Stribild

EVG/COBI/FTC/TDF elvitegravir/cobicistat/emtricitabine/tenofovir DF

Recommended initial regimen in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily with food. For people taking HIV therapy for the first time (treatment-naïve) or people with suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to the elvitegravir, emtricitabine, or tenofovir components of the regimen. Tablet contains 150 mg of the INSTI elvitegravir boosted by 150 mg cobicistat plus 200 mg emtricitabine and 300 mg tenofovir DF (TDF).

For adults and children 12 years of age and older weighing at least 77 pounds (35 kg).
Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney or liver problems. Stribild should not be started in individuals with estimated CrCl less than 70 mL/min and should be discontinued if CrCl decreases to less than 50 mL/min. Stribild is not recommended for patients with severe liver problems, or during pregnancy.

See the individual drugs contained in Stribild: Emtriva, Viread, and Tybost (elvitegravir is not available separately).

See package insert for more complete information on potential side effects and interactions.

Manufacturer

Gilead Sciences, Inc.
gilead.com
stribild.com
(800) GILEAD-5 (445-3235)

AWP

$4,076.39/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments